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Therapeutic Value of Radiofrequency Ablation of Hepatic Malignant Tumors  
 
Patients with primary and secondary malignancies of the liver are common. Liver is involved 
in 40% of adult patients who have primary tumors extrahepatic, and in cases with primary 
tumors, drained by the portal venous system (pancreas, large bowl, and stomach), liver is 
involved in as much as 75% of patients. Hepatocellular carcinoma (HCC) are the most 
common primary liver tumor, and metastatic liver tumours most often generate from 
colorectal carcinoma. Without treatment the median survival of HCC is 4 to 20 months and 
for CRM it is 5 to 13 months. 
Surgical resection of hepatic tumours is the best treatment modality with potential for cure in 
selected patients. According to a recent report from March 2006, the overall survival after 
hepatic resection of colorectal metastases at 1, 5, and 10 years was 93%, 47%, and 28%, 
respectively. In fact, only 5% to 15% of newly diagnosed primary or secondary liver 
malignancies are amenable to surgical resection. Use of other methods which do not involve 
resection has been in focus and can be divided into systematic techniques such as 
chemotherapy and arterial infusion chemotherapy and direct ablation treatments such as 
cryotherapy, ethanol injection and thermal ablation by use of lasers, microwaves or 
radiofrequency. RFA involves the localized application of alternating current that creates a 
marked agitation of ions in the target tissue. Agitation results in frictional heat around the 
electrode and thermal coagulative necrosis. 
The aim of the present study was to investigate the treatment efficacy of RFA and associated 
complications, based on available literature. 
The included studies were heterogeneous and clear conclusions were difficult to draw. The 
best overall survival for RFA treatment according to the included studies was 93% for 1-year, 
69% for 2-years, and 63% for 3-years. Major complications ranged from 0.9% to19.8% and 
minor from 4.7% to 32.5%.  
At present the radiofrequency ablation seems to be a promising therapy, but these results are 
based on the uncontrolled non-randomised trials. Randomised trials are not available to 
support the use of this technique. After search in Cochrane database only one review was 
present and this too compared different treatment modalities for the treatment of HCC. 
Therefore conclusive evidence based on randomised trials for potential survival benefit from  

















Primary and secondary malignancies of the liver are extremely common. The liver is second 
only to lymph nodes the most frequent site of metastasis from other solid cancers. Liver 
failure from extensive metastases often constitutes the main cause of death in patients with 
both colorectal cancer as well as a number of other common carcinomas. 
Malignant hepatic tumours can be divided into primary and secondary metastases tumours. In 
many parts of the world primary liver cancer or hepatocellular carcinoma (HCC) is a common 
malignant tumour and represents a major public health problem. HCC accounts for 70-80% of 
all primary liver tumours and it is the sixth most common cancer in the world (fifth in men 
and ninth in women).The liver is also often the clinically predominant organ site of metastatic 
malignant disease. In secondary metastatic liver tumours colorectal carcinoma is most 
common. Colorectal is the 4th most common solid tumor world wide, after cancer of the lung, 
stomach, and liver [1 discussion]. It is 2nd most common cause of cancer death in the UK [2 
introduction]. Colorectal metastases (CRM) of liver develop in 50% of the patients [3 
introduction].  Most colorectal carcinoma deaths can be because of metastases and in many 
patients the liver is the only and initial site. About 10-25% of patients have liver metastases at 
the time of primary diagnosis and another 20-25% patients develop metachronous liver 
metastases [4]. Without treatment the median survival of CRM is 5 to 13 months [5]. 
 
Surgical resection of primary and metastatic liver tumor is the optimal treatment modality 
with curative effect when disease is limited to the liver. 5-years survival after resection of 
HCC is given to be 25% to 30% [6]. In a study 3, 4, and 5-years survival rate after hepatic 
resection of colorectal metastases has given to be 73%, 65%, and 58% respectively [7]. 
Patients without extrahepatic disease and with good liver function and general condition are 
candidates for surgical resection. All liver metastases can be resected with at least 1 cm tumor 
free margin. Up to 75% of liver can be removed if the liver function is normal [4].  
 
Several patients with hepatic malignancies are irresectable due to insufficient liver function 
(ex cirrhosis), extrahepatic disease or because of tumors location. Only 10% to 20% of 
patients are therefore candidates for surgical resection [5], and other interventional methods 
are needed. Methods that do not involve resection can be divided into systematic techniques 
such as chemotherapy , intravenous or arterial infusion, and into direct ablation treatments 
such as cryotherapy, ethanol injection and thermal ablation by use of lasers, microwaves or 
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radiofrequency. Radiofrequency ablation (RFA) has recently been developed for the focal 
treatment of inoperable liver tumours, and as a complementary technique to surgical resection 
when metastases are spread to both liver lobes.  
 
The aim of the present study was to investigate the treatment efficacy of radiofrequency 
ablation (RFA), based on available literature, and to assess the value of this treatment 
modality, based on clinically relevant outcomes: Mortality, rate of recurrence, adverse events 
and  quality of life. 
Physical properties of RFA, different approaches and technical aspects; 
Radiofrequency ablation has become a widely used ablative technique for hepatic tumors. 
RFA involves the localized application of thermal energy to destroy tumor cells. In 
monopolar RF ablation, the patient is part of a closed loop circuit that includes a RF 
generator, an electrode needle and ground pads. An alternating electric field is created within 
the tissue of the patient. The liver tissue has relatively high electrical resistance in comparison 
with the metal electrode. The tissue ions attempt to follow the changes in direction of 
alternating electric current. This creates a marked agitation of the ions present in the target 
tissue that surrounds the electrode. The agitation results in frictional heat around the electrode 
and thermal coagulative necrosis. The discripency between the small surface area of the 
needle electrode and the large area of the ground pads causes the generated heat to be focused 
and concentrated around the needle electrode [8, 9, 10, 11]. 
 
The thermal damage caused by thermal heating depends on both the tissue temperature 
achieved and the duration of the heating of the tissue. Heating of tissue at 50-55°C for 4-6 
minutes produces irreversible damage to cells. At temperatures between 60°C and 100°C, 
immediate coagulation of tissue is induced, with irreversible damage to mitochondrial and 
cytosolic enzymes of the cells. At 110°C , tissue vaporizes and carbonizes. To get complete 
destruction of tumor tissue, the entire tumor volume must be heated to cytotoxic temperatures. 
RF induced necrosis is different from ordinary tissue death. In heat ablation the effected 
structures are subjected to thermal fixation. With staining techniques the tissue structure is 
preserved with absence of enzymatic activity. Modern radiofrequency system has a 
temperature sensor at the tip of the electrode to note the temperature. With temperatures 
higher than 110°C the tissue around the probe act as an electrical isolator, which further stops 
the passage of current and therefore decrease the effectiveness of ablation. With a cooled-
needle electrode, it is possible to enlarge the area destroyed by radiofrequency ablation 
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compared with that achieved with a bare electrode. This cooling process reduces the heat 
accumulation close to the needle and therefore allows diffusion of the current away from the 
needle. Treatment efficacy after ablation can be controlled by contrast enhanced CT or MR. 
Complete ablation is demonstrated by the absence of enhancement. Immediately after ablation 
it can see gas within the ablation zone with small amount of haemorrhage and reactive 
hyperaemia around the tumor. Despite the appearance of complete ablation, recurrence 
adjacent the ablated area can occur particularly where blood flow in adjacent vessels results in 
tissue cooling [8, 9, 10, 11, 12]. 
 
RF can be performed using image guidance with  percutaneous, laparoscopic approaches or at 
open laparotomy. At open laparotomy RF can be combined with liver resection, that is 
resection of one area of liver and ablation of the other. Open approach permits accurate RFA 
treatment for tumors near the inferior vena cava or the hepatic veins and to combine 
temporary hepatic vascular inflow occlusion called Pringle maneuver. Tissue perfusion has a 
direct impact on the volume of necrosis that can be produced. Inflow occlusion increases the 
size of the zone of necrosis by reducing intramural and peritumoral blood flow with a 
resultant decrease in flow related cooling of tissue but it also removes the protective effect of 
blood flow and as a result there is also increase risk of bile duct injury [12, 13]. 
RFA has been used as a treatment for osteoid osteoma, HCC, renal cell carcinoma, hyper 
functioning parathyroid adenoma. It has also been used to destroy lesions of the lung, kidney, 
bone, adrenal glands, spleen, breast, lymph nodes, pelvis, prostate, neural tissue, and liver [6, 
12 introduction, 14].   
 
There has been technical development in the treatment of RFA. The two main strategies that 
have been developed to increase the amount of ablated tumor parenchyma are use of several 
array needles or probe needles with radiofrequency energy applied through each array or 
probe and electrode cooling. Comparison of water cooled system with expandable array 
systems showed that the cooled tip needle induced larger lesions as a result of thermal 
ablation compared with the expandable multi array, but ablation with the expandable system 







The literature search was mainly conducted using database PubMed. The main period for 
research was November/December 2004. Search was also made in January/February 2006 but 
to a lesser extent. Words used to search the literature relevant to the question that is to be 
answered was hepatic or liver tumor, Radiofrequency ablation, Thermal radiofrequency 
ablation, Percutaneous / laparoscopic / open radiofrequency ablation, combined resection and 
RFA, complications of radiofrequency ablation and tumor malignancies.  
 
 Relevant articles from the reference list of the studies were also searched. Some articles are 
also from periodicals. Books on the topic of hepathology with clinical aspects and books on 
surgery were used from the library. The systematic review articles on complications and 
radiofrequency ablation are also included in this literature from the search from database.  
 
I tried to choose studies that include both primary and secondary liver tumors. Hence 
hepatocellular carcinoma and colorectal metastases (CRM) are the most frequent tumors in 
both categories some articles only concentrate on CRM and these studies are also included 
here. In other articles patients with tumor both from HCC and other sites are present. 
 
During the search in world literature, I found and overview, published in September 2003 
from the UK National Institute for Clinical Excellence [15], performed for the UK Procedures 
Advisory Committee. Until 2003 there was not published any randomised controlled trial 
(RTC), comparing the clinical outcome after RFA and surgery, treating primary or secondary 
liver malignancies.  
 
I therefore searced in the Cochrane Library for any RTC comparing RFA with any other 
treatment modality, and found one Cochrane report [16], referring two randomised trials, both 
comparing RFA with percutaneous ethanol injection [17] and microwave coagulation therapy 
respectively [18]. 
 
As there is still no published RTC comparing RFA with surgery, I selected publications with 





The aim of this study is to evaluate RFA efficacy and safety. It is important to have 
randomized control trials to answer this question. Adequate generation of the allocation, 
blinding and follow up of interventional and control group is the only way to have two groups 
that can be compared for outcomes. After search in the Cochrane database as mentioned 
above, there was only one review study on RFA [16], but in this review the radiofrequency 
was compared with two other treatment modalities for hepatic tumours. In this part I will 
present the results from six articles out of nearly 26, also including reviews and complications 
related to procedure. None of these studies are randomized trials. One study of Abdalla et al 
[7], is a retrospective study whereas the other five are prospective uncontrolled observative 
studies. Among these six studies, two studies use percutaneous, one laparoscopic and one use 
all three approaches for RFA. One study used combined resection and RFA. Another one 
compared only resection, resection+RFA, only RFA and only chemotherapy as treatment 
modalities. Two studies included only patients with colorectal metastases, and four studies 
had patients with mix tumor type.     
Abdalla et al. [7]  
The aim of the study was to examine recurrence and survival rates for patients treated with 
hepatic resection only, RFA plus resection and RFA only for colorectal liver metastases. They 
performed a retrospective analysis of patients operated for colorectal metastases confined to 
the liver. 418 patients were included in the study. All patients were treated between 1992 and 
2002. Patients were divided into two groups. Group 1, included 348 who were treated for cure 
with hepatic resection only, RFA+resection and RFA only. RFA alone or in combination was 
confined to the patients who were considered to be unresectable and in whom complete 
resection could not leave sufficient vascularized hepatic parenchyma to support post resection 
hepatic function. In the second group there were 70 patients and based on preoperative and 
intraoperativ findings were considered not to undergo curative therapy because of disease 
distribution or extent (but no extra hepatic disease) and too extensiveness of disease. These 
patients underwent chemotherapy (systemic, intra-arterial or intra-arterial +systemic 
chemotherapy). Of 348 patients from first group 190 underwent resection only, 101 
RFA+resection and 57 RFA only.  
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Preoperative chest radiograph or CT when indicated and abdominopelvic CT or MR was done 
in all patients. No patient underwent prior hepatic resection or RFA. Selection criterion for 
surgical treatment was complete tumor resection or RFA with preservation of sufficient 
hepatic parenchyma. RFA was not performed adjacent to major biliary structures. Patients 
with tumor close to major hepatic vein branch or major biliary structures were considered for 
RFA. All patients underwent open laparotomy. No patients were treated percutaeously. 
Itraoperative ultrasonograghy was used in RFA treatment to localize tumor. 
 Tumor Recurrence:  
In 57 patients who underwent RFA only, a total of 110 tumors were ablated. The number of 
tumors treated per patient was ranged from 1 to 8. Median tumor size was 2,5 cm. Recurrence 
of any kind occurred most often after RFA only. Recurrence in RFA only was 84%, in 
RFA+resection 63% and in resection only 52%. The dominant pattern was intrahepatic 
recurrence. Recurrence anywhere in the liver (without extra hepatic) was fourfold more 
frequent after RFA only than resection only (44% vs. 11%). Whereas it was double after 
RFA+resection than resection only (28% vs. 11%). 
Overall Survival: 
Median follow up time for first group, 348 patients, treated for cure was 21 months. Best 
survival rate was in patients who underwent resection only with 3-years survival 73%, 4-year 
65% and 5-year 58%. There was no significant difference in survival between groups treated 
with RFA+resection and those who were treated with RFA only. 3-years survival was 43% in 




                            
                                                                      Survival stratified by surgical treatment of cure 
Statistically significant difference was found in survival for those who were treated with RFA 
as a component of therapy and in those with chemotherapy.  
 
                                                                 
                                                   Survival stratified by treatment of “unresectable” patients 
Overall survival was best for patients treated with solitary tumors, intermediate for 2 to 3 
tumors and worst for >3 tumors.                         
 
Treatment of a solitary tumor by resection only provided survival better than treatment of a 
solitary tumor by RFA only.                                                                    
Recurrence Free Survival: 
It was best recurrence free survival for patients treated with resection only. There was no 
significant difference in recurrence free survival for patients treated with RFA+resection and 
those with RFA only. 
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                                                                                         Recurrence free survival                                   
Conclusion;                                
Hepatic resection is the treatment of choice for colorectal liver metastases. RFA alone or in 
combination with resection for unresectable patients does not provide survival comparable to 
resection, and provides survival only slightly superior to non surgical treatment. 
Solbiati et al; [14] 
The aim of the study was to describe the results of RFA in patients with hepatic metastases 
from colorectal carcinoma.The study included 117 patients with 179 metachronus colorectal 
liver metastases. They were treated with percutaneous RF ablation from July 1995 to October 
1999. Mean age of patients was 64.8 years. Mean diameter of tumors was 2.8 cm. (range, 0.6-
9.6 cm.). All metastases were at least 1 cm from the hepatic helium, gallbladder or bowl wall. 
All patients had undergone primary tumor resection prior to ablation. Malignancy of at least 
one tumor was obtained by ultrasonography guided aspiration biopsy. Patients could not 
undergo resection due to extra hepatic metastases, prior metastastectomy, age disease extent 
and co morbidity. 17% patients get systemic chemotherapy only before ablation, 72% before 
and after and 11% did not get any chemotherapy.  
All patients were examined by CT and biopsy before treatment. Cool –tip single or cluster 
electrodes were used under guidance of US. Mean procedure time was 45 minutes per session 
including tumor localization, treatment, and electrode removal and post procedure US. Follow 
up CT was performed 7-14 days after ablation. Areas that did not enhance with contrast were 
considered to be necrotic tissue. It was determined the effect of number of metastases on the 
time to new metastases and to death and the effect of tumor size on local recurrence. 
Results; 
A total of 229 RF ablations were performed in 117 patients with 179 tumors. Technical 
success was achieved in 98% (176) of tumors. Follow up ranged from 6 to 52 months. 
Mortality rate was 31% (36 patients). The time until death was not significantly related to the 
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number of metastases or the size of largest lesions. The mean time to death appears to 
decrease as the number of metastases or the diameter increases. 
 
TABLE. Time to Death by Number of Metastases  
Note.—NA = not available; median was not estimable in group due to the small number of 
occurrences among the cases in the group and/or to censoring of the longest times observed. 
Numbers in parentheses are percentages 
TABLE. Time to Death by Diameter of Largest Metastasis  
Note.—NA = not available; median was not estimable in group due to both the small number 
of occurrences among the cases in the group and to the censoring of the longest times 
observed. Numbers in parentheses are percentages. * Possibly biased. Mean and median for 
all patients are greater than respective estimates in all four subgroups, which reflects the 
distortions of censoring.  
Median survival for all patients was 36 months. 1, 2 and 3 years survival was 93%, 69% and 
46% respectively. 57% (67 patients) had new metastases. Median time of new metastases was 
12 months. The patients with no new metastases (tumor free suival) at 1 and 2 years after 
ablation were 49% and 35% respectively. Time to new metastases was not significantly 





TABLE 3. Time to New Metastases  
 
Note.—NA = not available; median was not estimable in group due to both the small number 
of occurrences among the cases in the group and to the censoring of the longest times 
observed. Numbers in parentheses are percentages. * Possibly biased. 
 70 lesions (39.1% lesions) of the 179 had local recurrence observed after treatment. Local 
recurrence rate at 18 months was 44%. No local recurrence was observed after 18 months. 
The lesions with no local recurrence at 6 months and 1 year were 69% and 60% respectively. 
Time to local recurrence decreased with increasing lesion size, while frequency of recurrence 
increased. Among those with local recurrence, retreatment does not appear to alter the like 
hood of survival. However there was a trend toward longer survival in patients with 
retreatment.  
Complications; 
Following complications were observed; 
• One case of perforation of right colon adjacent to an exophytic metastasis. Patient 
develop sign of perforation 2 days after ablation and underwent laparotomy. 
• Abdominal pain in one patient 3-4 hours post procedure. Tumor was treated at the 
dom of the liver. Patient had orthostatic hypotension and intraperitoneal hemorrhage 
was as noted on CT scan.   
Conclusion; 
RF ablation is an effective method to treat hepatic metastases from colorectal carcinoma. 
Lannitti et al: [6] 
The objective of the study was to observe the efficacy of hepatic radiofrequency ablation in 
the treatment of unresectable hepatic malignancies.  
123 patients with hepatic malignancies were treated with percutaneous, laparoscopic and open 
RFA from January 1998 through September 2001. Patients had histological documented 
hepatic malignancies. They were treated with RAF if it was unresectable tumors, not 
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sufficient liver function, medical condition that inhibited abdominal surgery and tumors that 
could not be treated by resection. Percutaneous RF was performed under conscious sedation, 
surgical RFA under general anaesthesia and with intraoperative US. For laparoscopic 
procedure US was also used. An internally cooled clustered RF electrode was used for all 
ablations. In patients with 4 or more lesions, operative RFA was used.  
 Average age of patients was 65 years. Of 123 patients, 52 patients had metastasis colorectal 
cancer, 30 hepatocellular carcinoma. 41 patients had other histological findings including 
hepatoblastoma, sarcoma, intrahepatic cholangiocarcinoma and metastases from other sites 
(renal, breast, melanoma, oesophagus, lung, gastric, gallbladder, carcinoid, thyroid and 
neuroendocrine tumors). It was performed a total of 168 RFA sessions. Of 168, 132 were 
treated with percutaneous, 33 with open surgery and 3 with laparoscopic RFA. Due 
recurrence and incomplete ablation several patients had ablation several times. For all 
ablations cooled clustered RF electrode was used. Post procedural systemic chemotherapy 
was offered to patients on the basis of their performance status and the histological features of 
their disease.   
 
 
Results and complications; 
Median follow up time was 20 months (range, 1-47 months). Median tumor size was 5.2 cm 
(range, 0.5-15.0 cm). Follow up for all patients included imaging every 3 to 6 months. 0verall 
survival for patients with metastatic colorectal cancer at 1 year was 87%, at 2 years 77% and 
at 3 years 50%. For patients with hepatocellular carcinoma overall survival was 92% at 1 
year, 75% at 2 years and 60% at 3 years.  
• Mortality rate was 0.6% (of total RFA sessions) due to cerebrovascular accident.  
• Total morbidity rate was 7.1% for 168 ablation sessions. The most commonly 
encountered patient complaints are focal discomfort at the probe entry site and flu like 
symptoms known as post ablation syndrome. 
• Hepatic abscesses occurred in 4 patients. Each patient had significant risk factors such 
as advances cirrhosis, underlying chronic cholangitis and previous left sided 




Hepatic RFA is an effective treatment option for patients with unresectable hepatic tumors. 
Careful patient selection based on tumor size, location and number and on patients clinical 
status should determine the choice of treatment. Further controlled trials are needed to 
determine the effect of hepatic RFA on long term survival. 
T. M Pawlik et al: [11] 
The objective of the study was to examine the safety and efficacy of hepatic resection 
combined with RFA.  
172 patients were included in the study and all underwent combined hepatic resection with 
intraoperative RFA. Inclusions criteria were histologically confirmed primary or metastatic 
hepatic malignancies with no extra hepatic disease. To be eligible, patients had to have 
multifocal hepatic disease that was unresectable due to location of tumor or volume of the 
liver involved. Patients were surgically unresectable for cure because of number or bilobar 
loction of the tumor, tumor location to major vascular structures, and the presence of cirrhosis  
hepatic reserve not sufficient to tolerate major hepatic resection. Patients were considered 
candidates for RFA even if the tumor was localized near major hepatic or portal vein or vena 
cava inferior, but they were excluded if tumor involved bile ducts because thermal heat from 
RFA could destroy major bile ducts. 
Serum laboratory tests were taken of all patients and they were evaluated with baseline 
history. CT or MR scan of the abdomen and pelvis, and the chest radiograph was taken. 
Patients were excluded if they had less platelet count or if prothrombin time was prolonged. 
Those patients with less white blood count or a bilirubin>2.0 mg/dl were also excluded. 
All patients were treated surgically with both RFA and resection in one operation. Initial 
exploration was performed on entering the abdomen to see if extrahepatic disease was 
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present. An intraoperative ultrasound was also used to localize the tumor and find its 
proximity to vessels. After treatment same serum blood tests were obtained on days 1, 7 and 
30 that was taken before procedure. It was also performed CT or MR of chest and abdomen 
postoperatively at different time interval. Recurrence was detected by CT/MR or via biopsy 
diagnosis. 
Results; 
172 patients were treated using both resection and RFA. Median age was 56.2 years. Majority 
of the patients had metastases from colorectal cancer. Other tumor forms are shown in table. 
 
Patients with noncolorectal tumors had lesions restricted to liver and was responding to or 
was stable on systemic chemotherapy. A total of 737 tumors were treated, 350 with RFA and 
387 with resection. The median number of tumor per patient was 3 (range, 2-21). The median 
number of tumor surgically treated per patient was 2 (range1-9) and those with ablation was 1 
(range, 1-12). Median operative time for the combine procedure was 3.0 hours (range, 1- 8.13 
hours). After removal of the index lesion or lesions, the remaining unresectable lesions were 
treated with RFA following a standardized treatment. Combing RFA with resection was 
generally well tolerated with minimal complexity or morbidity to the operation. The median 
operative time for combined procedure was 3.0 hours (range 1-8.13 hours) with a median 
blood loss of 200cc. 
Complications; 
RFA associated complication was one partial thickness thermal injury to stomach. 
Postoperative complication rate was 19.8% including 2.3% mortality rate. A number of 
complications were minor and not necessarily related to procedure. Prolonged postoperative 
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ileus, urinary tract infections, and pleural effusion were not necessarily related with 
procedure. Intermediate complications included tachycardia, biloma, perihepatic abscess and 
pneumonia.There was no relation between resection extent and number of tumors ablated with 
postoperative complications. Adult respiratory distress syndrome, multisystem organ/hepatic 
failure, postoperative bleeding and pulmonary embolus were uncommon major complications  
and occurred in the patients who died postoperatively. 2 of the deaths among 4 were related to 
liver failure and one death was due to postoperative bleeding and cardiac arrest. 
                         
                                                                Postoperative complications and deaths 
Recurrence: 
Median follow up time was 21,3 months with tumor recurrence rate 56,9% (98 patients). The 
site of first recurrence was isolated to the RFA site in 8 patients (8,2%), a non-RFA hepatic 
recurrence in 38 patients (38,8%), a non-RFA hepatic recurrence plus distant disease in 31 
patients (31.6%) and isolated distant disease in 21 patients (21.4%). The median time to 
failure was about 7,5 months in all patients. Most frequent distant disease was pulmonary 
metastases. RFA recurrence in patients was 8,2% that means 8 out of 172 recurred, but there 
were only 8 treatment site failure out of 350 tumors treated with RFA (2.3%). 
 
   
                            Details of tumor recurrence after hepatic resection and RFA: overall recurrence rate    
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The only factor that affected time to recurrence was the total number of tumors treated.There 
was statistically significant difference in time to recurrence in those patients who had more 
than 10 tumors treated (tumors treated combined with resection and ablation). Patients more 
than 10 tumor had shorter median disease free survival time of 2,3 months as compared to 
those who had fewer tumors than 10, that is 7,6 – 10,3 months. Median time to recurrence was 
not effected by the number and size of tumor treated with RFA. In all cases median time to 
recurrence was <12 months.                                   
Survival: 
Overall survival time was 45,5 months. In the follow up time mortality rate was 34,8% (60 
patients), and 65,2% (112 patients) were still alive. Significant factors affecting overall 
survival were type of tumor and amount of blood loss. Patients with noncolorectal metastases 
had a median survival time of 59 months that was better than colorectal metastases with 
median survival time of 37.3 months. The amount of surgical blood loss also significantly 
affects overall survival.   
 
Surgical blood loss had significant affect on survival. Those with >1000 cc blood loss had a 
median survival time of 30.5 months. Patients with <250 cc blood loss had median survival of 
42.6 months and <250-1000 had 56.6 months. Other factors such as age, number of RFA 
tumors, type of surgery and total number of tumors treated did not significantly affect survival 
on univariate analysis. Patients with synchronous colorectal metastases had a better overall 
survival as compared to patients with metachronous metastases. Size of RFA tumor was the 
only factor that significantly affected survival. Lesion > 3 cm had a higher like hood of death 




Resection combined with RFA provides a surgical option to patients who are unresectable, 
and this may increase long term survival. 
Chung M. H. et al; [19] 
The purpose of the study was to analyse efficacy of laparoscopic interoperate ultrasound and 
laparoscopic RFA in patients with unresectable hepatic tumors.  
Patients unresecable for primary or metastatic tumors without extra hepatic disease were 
included in the study. Patients were unresecable if they had tumors number greater than 4, 
bilobar disease and localization of tumor near major vascular and biliary vessels. Patients in 
the study were at least 18 years old with a life expectancy of at least 4 months. Pregnancy, 
active infection and chemotherapy/ biotherapy/radiotherapy were exclusions criteria. Patients 
who could not undergo laparoscopy or laparotomy, those with tumors occupying more than 
40% of the liver and those who had received hepatic arterial infusion pump were also 
excluded from study.  
Study included 27 patients and all these underwent complete history and physical 
examination, serum tests, chest radiography and other imaging. Laparoscopy was used to 
examine any extra hepatic tumor and all eight liver segments. 15 gauge needle RFA was used. 
In second year of study larger lesions were ablated using a cool tipped probe electrode. Probe 
tract was cauterized as the RF needle was withdrawn after completion of the ablation.  
All patients underwent laparoscopic RFA. Among the 27 patients 25 had received adjuvant 
therapy and 11 had undergone abdominal surgery. Mean age of patient was 59 years. Total 
number of ablated tumor was 85. Tumor type was hepatocellular carcinoma and metastases 
from colon, breast cancer, carcinoid, lung adenocarcinom, sarcoma, tongue and melanoma.  
Tumor type NO. of paients No. of tumors 
Melanoma 8 31 
Colon adenocarcinoma 6 14 
Breast carcinoma 3 7 
Hepatocelluar carcinoma 4 10 
Carcinoid 3 14 
Lung adenocarcinoma 1 3 
Srcoma (leiomyosarcoma) 1 4 
Tongue (adenoid cyst) 1 2 
Total 27 85 
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 Results;  
85 malignant tumors were ablated. The mean diameter of tumor was 2.6cm (range, 1.3- 5cm). 
Most of the patients had multiple tumors with mean 3.1 tumors (range, 1-8 tumors). Of the 27 
patients 14(52%) had bilobar hepatic tumor, 7(26%) had centrally located tumor and 6(22%) 
had tumor confined to the right lobe of the liver. No patient was found to have extra hepatic 
tumor by laparoscopic examine. However by laparoscopic intraoperativ ultrasound it was 
found that 10 (37%) had additional hepatic lesions which were not identified preoperative 
imaging. these lesions were for the most small in size, <1cm, located on the surface or near 
the surface of liver. These additional tumors were also treated by RFA. Mean follow up time 
was 14 months (range, 2-27 months). Mean hospital stay for all patients was 1.3 days (range, 
1-7 days).  
Mean survival was 10 months (range, 2- 18 months). 11 (41%) patients were disease-free. At 
the end of the study 6 (22%) were alive with disease and 10 (37%) have died with disease. 
Local recurrence rate in patients was 4 (15%) and local tumor recurrence was 4 (4.7%). local 
recurrence occurred in one patient with hepatocellular carcinoma. The other three patients had 
metastatic melanoma. 
Complications; 
There was only one postoperative complication. It was postoperative bleeding in one (4%) 
patient because of underlying thrombocytopenia. No treatment related mortality was seen.  
Conclusion; 
Laparoscopic RFA and intraoperativ ultrasound constitute a safe and accurate method for 
ablation of unresectable hepatic tumors. 
Chen MH et al; [20] 
The aim of the study was to investigate the treatment efficacy of radiofrequency ablation 
(RFA) of hepatic malignant tumors and the relevant complications. 
 338 patients with 763 hepatic tumors underwent 565 ultrasound guided percutaneous RFA 
from 1999 to 2004. All patients were diagnosed by biopsy at least on one lesion. Mean age for 
men was 59.1 years and for women it was 58.6 years. 204 patients had hepatic cellular 
carcinoma (HCC) with 430 tumors with mean diameter of 4.0 cm (range 1.2-10.8 cm). Of  
204 patients with HCC 48 were in stage I-II and 156 patients were in stages III-IV according 
to UICC-NTM staging system. Of total 338 patients, 134 patients had metastatic liver 
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carcinomas (MLC) with 333 lesions with a mean diameter of 4.1 cm (range 1-10.0 c.m). 11 
patients had extrahepatic metastases when the first RFA was performed.  
 
Primary tumor site of MLC Number of patients  
Gastric and colorectal tract 96 (71.6%) 
Breast cancer 16  
Lung cancer 10 
Pancreatic cancer 5 
Other organs 7 
Total patients 134 
 
61.8% patients (209/338) had tumors larger than 3.5 cm. 51 patients had 54 tumors adjacent 
to gastrointestinal tract and 46 patients with 51 tumors adjacent to gallbladder in this group. 
The RF system used was 460 kHz generator  and the electrode contained nine hook-shapes 
prongs that could deployed from the canula. 93% of the patients were treated using 
established protocol. The treatmet protocol was decided according to the ablation range. 
Ultrasound was used to monitor the electrode placement. All patients underwent percutaneous 
RFA under general anesthesia. For irregular tumors larger than 5 cm and near gastrointestinal 
tract CT within 24 h after the treatment was used to detect any residual viable tissue and to 
observe possible complications. 1 month after ablation contrast enhanced CT was performed 
to evaluate tumor respons to therapy. Complete ablation was considered to achieve if ablation 
zone was beyond tumor border, margin of ablation was clear and smooth and no contrast was 
detected within or near tumor. The patients were follow up later by serum α-fetoprotein 
(AFP), abdominal US and CT. Follow up period was 3-57 months. 
Results; 
The ablation success rate of initial RFA was 94,8% (723/763 tumors).Complete ablation 
success after the first RFA based on the CT findings was 93.3% (401/430 tumors) for HCC 
and for MLC was 96.7% (322/333 tumors). Overall residual rate was 11.2% (38/338 patients) 
of which 31 cases (81.6%) had tumor larger than 3.5 cm. Success rate for tumor larger than 
3.5 cm was 85.2% (178/209 patients). 
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No. of local 
recurrence 
(%) 
HCC 204 430 4.0 401 (93.3) 34 (7.9) 
MLC 134 333 4.1 322 (96.7) 35 (10.5) 
Total 338 763 4.1 723 (94.8) 69  (9.0) 
 
For tumors adjacent to bowel ablation success rate was 83.3% (45/54 tumors) it was 86.3% 
(44/51 tumors) for tumor adjacent to gallbladder. Local tumor recurrence was found in 34 of 
HCC patients (7.9%) and 35 of MLC patients (10.5%) after follow up of 3-57 months. 40.5% 
of patients received additional 2-11 RFA treatments because of metastases or recurrence. The 
overall survival rate of 300 patients with malignant liver tumor after RFA was 80.6%, 60.1% 
and 50.4% for 1st, 2nd and 3rd year respectively. The survival rate for metastatic tumor for 1, 2 
and 3-year was 75.3%, 50.2% and 25.1% respectively. HCC patients survival after 1, 2, 3-
year was 84.6%, 66.6% and 63.1%. The overall survival rate was higher in HCC group than in 
MLC. 
Complications; 
Major complications occoured in 2.5% procedures (14/565). Minor complications consisted 
of bellyache, shoulder pain, breath-related ight superior bellyache, fever and transient hepatic 
dysfunction.  
Major complications Number of patients 
hemorrhage 5 
bile leakage 2 
colon perforation 1 
stricture of bile duct 2 
cholecystitis 1 
hemothorax 2 
Skin burn 1 
 
Conclusion; 
RFA is minimally invasive local treatment and has become an effective and safe alternative 
for patients of hepatic malignant tumor, even of advanced liver tumor, tumor recurrence, and 
liver metastases. 
 23
Complications of RFA; 
RFA has proven to be safe and efficacy method to treat the malign tumors of liver. It has 
received increasing attention as a promising technique. There are some complications that are 
attended with treatment procedure. Early detection and proper management of complications 
are possible only if the physician performing RF ablation understands the broad spectrum of 
complications. This can minimize the complications and help to exclude high risk patients.  
Complications can be of those related to imaging guided electrode placement, such as 
bleeding, infection, tumor seeding, and pneumothorax and those that are related to thermal 
therapy. Complications related to thermal therapy can damage organs adjacent to ablated 
tumor and grounding pad burns [21]. 
Bleeding; [21, 22] 
Bleeding is an important complication that can occur during and immediately after ablation. 
Complication can also depend on tumor location and the character of underlying parenchyma. 
Coagulation disorder in patients with end stage liver disease, patients with cirrhosis, higher 
vascularity of hepatocellular tumors compared to metastases are some factors that can 
contribute to bleeding complication. The bleeding may also develop from direct mechanical 
injury to the vessels by the RF needle rather than from thermal injury to the vessels. An 
arteriovenosus fistula or pseudoaneurysm can also develop from direct traumatic injury.  
In order to minimize bleeding, screening for coagulopathy before procedure, placing of the 
RF needle electrode safely without transversing major vessels, cauterization of the needle 
tract after ablation and not to reposition needle many times can be preventive. Colour Doppler 
of the needle tract can also be helpful in early detection of arterial bleeding. Detection of 
important clinical signs and analysis of blood tests is essential for early detection of bleeding 
[22]. 
 
                  Emergency angiogram shows brisk arterial bleeding from hepatic artery [21] 
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Infection; [21, 22] 
Sepsis and abscess can be seen after ablation procedure. Risk factors for hepatic abscess or 
sepsis are bacterial contamination of the hepatic parenchyma and biliary tract, bilioenteric 
anastomosis and bilioenteric fistula. Diabetic patients are at greater risk for infection because 
of their low immune system.  
Diagnosis of abscess can sometimes be delayed because fever is not only symptom of abscess 
but it is also a symptom of postablation syndrome which is seen frequently after ablation. 
Therefore, if a fever lasts for over 2 weeks, the possibility of abscess formation should be 
considered. Prophylactic use of antibiotics may be helpful in patients with high risk of 
infection. New gas bubbles in ablated area not seen previously can be sign of abscess 
formation. Minimal amount of air can be seen immediately in CT scan after RF in ablated 
area and these should not be misdiagnosed as abscess. These minimal air bubbles usually 
resolve within 1 month. Most abscess can be treated with aspiration or percutaneous catheter 
drainage coupled with antibiotics.  
 
 
                    One week follow up shows a gas forming abscess (arrow) in the ablated area with a perihepatic fluid [22] 
 
Tumor seeding; 
Tumor seeding usually occurs 3-12 months after RF ablation. Seeding of the needle track, 
pleura, or peritoneum can be seen depending on tumor location, and is more likely to occur 
with aggressive tumors in a subcapsular or superficial location. Poor differentiated tumor, 
hepatocellular carcinoma are risk factors for tumor seeding [21, 23, 24, 25]. Furthermore it is 
recommended to avoid treating an exo-phytic tumor percutaneously [22]. 
There can be different mechanism for tumor seeding. Tumor cells may adhere to biopsy 
needle or electrode during its withdrawal. With bleeding tumor cells may come into track. 
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Cells may be forced into the track by sudden intratumoral hyperpressure. Cells can also be 
driven in when saline is injected into the tumor. Other risk factor for seeding is preprocedural 
biopsies, poor differentiation of the tumor, no cauterization of the electrode track and a 
perpendicular approach to subcapsular tumors [23].  
To avoid tumor seeding the number of punctures and the amount of repositioning of the RF 
needle should be minimize and a sufficient portion of normal hepatic parenchyma along the 
needle tract is required, especially in the case of subcapsular tumor [22]. Sufficient RF energy 
to heat the tissue surrounding the electrode before it withdraws (“hot withdrawal”) induces 
coagulation and this can reduce complications of tumour seeding and bleeding [21, 24] 
 
                                          
                                               Tumor seeding after RF ablation of a metastatic liver nodule [21] 
 
Thermal damage to nontarget structures; 
The heat from RF can also coagulate irreversibly and damage the organs adjacent to ablated 
tumor. Subcapsular location of the tumor can give raise to complications to adjacent organs. 
Radiofrequency is supposed to destroy the tumor with a safety margin of 0.5 -1 cm of healthy 
parenchyma. This leads to heating of structures that are located with in 0.5-1 cm from tumor 
margin [26]. The gallbladder, bile ducts and bowl are sensitive to thermal energy. Bile duct 
strictures, cholecystitt and perforated bowl can be seen. Perforation of the gastrointestinal 
wall has been observed only when the target lesion is within 1 cm of the liver capsule or 
adjacent to a gastrointestinal lumen [21]. Of the adjacent organs, the colon is most sensitive to 
heat because of its thin wall, and colon perforation is the most frequently reported 
complication involving adjacent organs [26]. Gastric complications are rare because of the 
relatively thick wall of the stomach. Small bowl because of its mobility is protected as 
compared to fixed colon.  
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Ground pad burns;  
The use of high current RF technique has increased the risk of burns at the ground pad site. A 
larger surface area of the return ground pad is required for more energy to be dispersed. 
Serious skin burns were reported during early experience when insufficiently sized ground 
pad were use. This complication has become relatively rare because large ground pads are 
used and guidelines to prevent burn are followed [21, 22].  
 
Thoracic complications; 
When tumor mass is located in the dome of the liver, pneumothorax and hemothorax can 
occur. If a patient has symptoms like dyspnoea or chest pain after ablation, chest radiograph 
or CT should be taken to exclude these complications. Diaphragmatic thermal injury is also 
possible when tumor is present in the dome of the liver. Diaphragmatic injury is self-limited 
with conservative treatment [22]. 
 
Postablation syndrome; 
This is considered as a minor complication. It consists of a group of symptoms that are pain at 
the ablation site, shoulder pain, fever, nausea, vomiting, arthralgia, headache, tiredness, and 
loose stools. Post ablation occurs within a few days after ablation and persists for 2-8 weeks. 
This is often seen after ablation of large tumors (> 4-5 cm in diameter). Pain medication and 
rest is the treatment [21].  
 
Risk factors for complications: 
RF ablation of subcapsular tumours carries a higher risk of intraperitoneal bleeding, 
subcapsular haematoma, seeding and visceral damage. Ablation of central tumours 
predisposes to biliary tract and central vessel damage. Complications after RF of 
hepatocellular carcinoma are more common in child-Pugh class C than in class A or class B. 
In percutaneous approach thermal damage to neighbouring organs is seen exclusively. Tumor 
seeding is also seen often in percutaneous approach because the impossibility of coagulating 
the electrode track for superficial tumor. For large and multiple tumors where extensive 
procedures are used, there is a higher risk of liver failure, ground pad skin burn, 
myoglobenimea or myoglobinuria, thrombocytopenia and central hyperthermia [23].   
Complication rate increases also with increasing numbers of punctures, larger volumes of 
necrosis, more advanced Child Pugh class and treatment of lesions close to the diaphragm, 
into the liver hilum, close to vessels or viscera [12]. 
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Different strategies for prevention from complications can be, not to perform ablation on 
patients with high risk of complications. Therefore coagulopathy, underlying hepatic reserve 
and tumor location to major structures, bile ducts, and intestine should be evaluated before 
treatment. Another method can be selection of the treatment procedure which gives proper 
visualization of tumor and adjacent structures. The open and laparoscopic approaches are 
better in isolating the lesion from adjacent structures and give better control of bleeding from 
the surface of the liver [22].     
Rate of complications can also be lowered by avoiding Pringle maneuver during 
radiofrequency ablation in cirrhotic patients, caution when treating patients with bilioenteric 
anastomosis and who having a tumor less than 1 cm from adjacent organs, especially colon 























The most striking characteristics from the present literature study is that evidence for a 
beneficial effect of RFA is weak, and even the UK report from 2003 [15] seems to 
recommend RFA treatment despite lack of evidence. The report concludes: “RFA has the 
potential to cure some patients and can prolong survival in many others”. But the literature 
basis for this report was one single prospective report with low quality and further three small 
patient series with very limited information. Even the UK report seems to recommend RFA in 
spite of very poor evidence base.  
 
Without treatment the median survival of HCC is 4 to 20 months and for CRM the median 
survival is 5 to 13 months is reported from one center [5]. In patients with metastatic disease 
confined to liver and without any treatment, another report gives median 9 months [27]. 
Those with solitary tumours and without any active treatment have a 3-year survival rate of 
20% [28].  
 
In this paragraph I will describe the results from six selected articles. The best overall survival 
rates according to the results from the six articles included in the present study for RFA are 
93% for 1-year [29], 69% for 2-years [29], and 63% for 3-years [20]. There is only one study 
that gives 4-years survival rate of 22% [7]. This survival rates compares favourably with the 
natural course of the disease, and the evidence for treatment benefits, mostly lacking in the 
UK report, now seems to increase. As the mean survival is concerned it is 36 months in one 
study [14] that varies a lot from another with 10 months as a mean survival rate [19]. Two of 
the articles [7, 11] among these six, used combined RFA and resection as a treatment 
modality. Abdalla et al [7] gives 43% and 36% survival rates at 3 and 4-years. The other study 
[11] gives only result in the form of mean survival of 45.5 months. From these results one can 
see that 43% survival rate at 3-year with resection+RFA of CRM is lower than 50% in 
another study for CRM [6] where only RFA was used, but it is higher than 37% in the study 
[7] where RFA was used. Accordingly, it is difficult to give exact figures for survival after 
RFA as a treatment modality, as the variation is significant. Surgical resection of primary and 
metastatic liver tumor is the optimal treatment modality with curative effect, offering a 5-
years survival rate between 20% and 35% [30, 31]. The 3, 4, and 5-years survival rate after 
hepatic resection of colorectal metastases was 73%, 65%, and 58% respectively In Abdalla’s 
report [7]. According to a recent report from March 2006 [32] with a follow up period of 10 
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years, the overall survival after hepatic resection of colorectal metastases at 1, 5, and 10 years 
was 93%, 47%, and 28%, respectively. From these results of resection we can see that 
resection has higher overall survival than only RFA and resection+RFA. Local recurrence 
was 4.7% after a mean follow-up period of 14 months in lesions treated with laparoscopic 
RFA [19] versus 7.9% for HCC and 10.5% for metastases after follow-up 3-57 months, 
treated with percutaneous RFA [20]. Local recurrence was seen in 9% of patients after only 
RFA, in 5% after RFA+resection and 2% after resection only in the same way intrahepatic 
recurrence was seen in 44% patients after RFA only, in 28% after RFA+resection and in 11% 
after resection only [7]. According to these results local and intrahepatic recurrence is lowest 
after resection and it is lower in resection+RFA than in RFA only. Among these six studies 
the mortality rate differs from 3.4% [29] to 37% [19] after 7 months of ablations and after a 
mean follow up period of 14 months (range, 2-27 months) respectively. Additional new 
tumors were identified in 37% of patients by laparoscopic RFA that was not detected on 
preoperative imaging. 
 
The overall survival at 1, 3 and 5-years  was 71%, 21% and 14%  in Gilliams report [2]. This 
is the only study that gives a survival rate at 5 years, all other studies gives survival results 
mainly up to 3-years. This survival rate of 14% after RFA is much lower than survival rate of 
58% at 5-years after resection [7]. In White T et al study [3] survival rate at 1-year was 75% 
that correspond to 71% in Gilliams report, but still there is a wide range of difference in 
survival rate in all studies. Intrahepatic recurrence after a mean follow up of 14.6±9.2 months 
and 17 months was 53.9% in one study [33] and 50% in another [2] after the RFA treatment 
of mix tumor and CRM respectively. Again we can see that the intrhepatic recurrence of 50% 
is much higher than 11% after resection and 28% after RFA+resection [7]. 
 
Complications related to RFA procedure is divided in the most studies into major and minor 
complications. Major complications were defined as events that if left untreated could 
threaten patient’s life, increase hospital stay and morbidity [24, 26, 34]. Major complications 
ranged from 0.9% [34] to 19.8% [11]. and minor from 4.7% [24] to 32.5% [25]. In some 
studies death is included in major complications while in other it is given separately. The 
most common complications were hepatic abscess, peritoneal haemorrhage, skin burn, 
perforation of gastrointestinal tract and biliary leakage. According to a review article of 3670 
patients [23] the complication rate was 7.2%, 9.5, 9.9 and 31.8% after percutaneous, 
laparoscopic, simple open and combined open approaches respectively. The mortality rate 
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was 0.5%, 0%, 0% and 4.5% respectively [23]. Two large studies [22, 24] give on the other 
hand percutaneous complication rate 2.4%. In another study [19] with laparoscopic RFA with 
27 patients there was 1 case of postoperative bleeding. With combined RFA+resection 
complication rate was 19.8% including death [11]. Complication rates can varies a lot in all 
these studies. According to these results the complication rate is higher in resection +RFA 
than in only RFA treatment, and it can be because the RFA is a less invasive procedure. 




Mortality rate % 
(no. of patients) 
Number of patients and complications 
23 0.5% (20) 7 (0.2%)   Sepsis 
7 (0.2%)   liver failure 
4 (0.1%)   cardiac complications 
1 (0.0%)   peritoneal bleeding 
1 (0.0%)   bile duct stricture 
 
22 0.09% (1)                  Peritoneal bleeding 
 
24 0.3% (6) 2               intestinal perforation 
1               peritonitis 
1               tumor rupture, massive haemorrhage 
1               stenosis of right bile duct 
1               sudden death of unknown cause 
 
34 0.3% (1)                  Liver decompansation 
 
26 1.6% (5) 1               liver insufficiency 
1               colon perfusion 
3               portal vein thrombosis 
 
11 2.3% (4) 2               liver failure 
1               postoperative bleeding 
1               cause not given 
 
                                 Complications as a cause of death and mortality rate in studied articles 
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Some factors can affect the outcome of results in different studies and these should be 
considered when analyse the results. The length of follow up can be different in different 
studies such that the results can be different in one study with very short follow up period as 
compare to other in which the follow up period can be comparatively longer. Inadequate 
length of studies can also affect results like local recurrence, intra or extra hepatic recurrence. 
Randomised controlled trials of radiofrequency ablation are lacking [9]. Outcome following 
RFA can be difficult to interpret, since most studies report recurrence per lesion rather than 
per patient, and most studies report outcome for patients with mixed tumor type using 
different techniques of ablation with different equipment [7]. Inclusion criteria for patients 
can also be different. As mentioned above patients with unresectable are the main criteria for 
treatment of RFA, but other additional factors like chemotherapy as an adjuvant treatment can 
be inclusion criteria in some studies [1, 3] but it can be exclusion criteria in other [19]. 
Technical development in RF treatment can give difference in results from newly published 
studies as compare to earlier studies. 
 
All these results are from uncontrolled non-randomized studies, and there is lack of evidence 
based medicine to conclude that RFA is very efficient treatment method for liver tumors. To 
answer this question it is important with RCT and comparing of controlled group with 
interventional group. After search in Cochrane database it was only one review article [16] on 
two randomised clinical trials. One trial [17] including 102 patients, compared RFA versus 
percutaneous ethanol injection for small hepatocellular carcinoma. Another trial [18] 
compared RFA versus percutaneous microwave coagulation for 72 patients, but the results 
from these trials cannot be generalized because these trials compare two different treatment 
modalities. The only method to get results that can conclude about the treatment efficacy of 
RFA is to compare one control group without treatment or placebo with interventional group 
in which patients get RFA. But it is ethically not possible because patients with liver tumors 
can not be left untreated when results from the trials show that resection can be curative 
treatment for patients that have disease confined to liver and with good hepatic function, and 
that RFA may give long survival than if they left untreated. More randomised trials and 








Initial treatment with RFA in patients with unresectable hepatic liver tumours or poor liver 
function seems to be more effective compared to other local therapies. A review article [9] 
included one study [35] in which RFA and cryotherapy were compared. Procedure related 
complications were higher (41%) in cryotherapy as compared to 3% in RFA. Tumor 
recurrence was 2% in lesions treated with RFA, compared to 13% in those treated with 
cryotherapy. In another study [36] from the same review, RFA led to higher frequency of 
complete necrosis (90%) of tumors than with percutaneous ethanol injection (80%) but the 
complication rate was higher with ablation (2%) than with ethanol injection (0%). 
 
Advances in chemotherapy are improving the survival in unresectable CRM. 5 fluourouracil  
(5-FU) and folinic acid (FA) remains the foundation of treatment and gives an improvement 
in median survival from 6 to 12 months. Two recently introduced drugs oxaliplatin and 
irenotecan, in combination with 5-FU-FA gives a median overall survival of 15-20 months. 
With the addition of bevacizumb the median survival appears now to exceed 20 months. 
Similar results can be obtained with hepatic arterial infusion of 5 –FU-FA although the 
toxicity is quite distinct from that seen in systemic administration of 5-FU [28].  
Chemotherapy can reduce tumor volume and patients with unresectable disease can undergo 
effective resection [2].  
 
Hepatic resection is the only treatment of cure for patients with liver tumors who have disease 
confined to the liver. The operative mortality for major liver resection has reduced with 
development in the operative techniques and postoperative care, but mortality is still 
significant. According to review article [4] operative mortality ranged from 0% to 7% with 
haemorrhage, sepsis and liver failure as the causes of death, and the morbidity between 22-
39%.Another recent report from 2006 [32] had a 5-years survival rate of 47% after a 10-years 
follow up period. Pawlik et al [11] and two review articles [12, 4] gives result from resection, 
RFA and combined RFA+resection and it seems that both mortality and morbidity is higher 
with resection as compare to other two modalities, and that RFA being the minimal invasive 
procedure has lowest rate of mortality and complications. As survival is concerned, resection 
gives higher overall survival than other modalities [7].  
 
 33
Radiofrequency ablation is just one of the options for patients with hepatic tumors. Selection 
of RFA should be made only after consideration of the alternative therapies option. Patients 
should be considering for hepatic resection if there are not contraindications. At present the 
radiofrequency ablation seems to be a promising therapy but this is based on uncontrolled 
trials, and as mentioned earlier even the UK report from 2003 [15] seems to recommend RFA 
treatment despite lack of evidence and the literature prospective report with low quality and 
patient series with very limited information. The evidence based knowledge about the 
radiofrequency ablation for the treatment of hepatic tumors is lacking. Randomised trials are 
not available to support use of this technique. After search in Cochrane database only one 
review was present and this too compared different treatment modalities, and trials with a 
control group was lacking. But it is ethically not possible to perform randomised trials with 
control group giving placebo or no treatment; because patients with hepatic tumors can not be 
left untreated when studies conclude that there are treatment options for such patients.   
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